First, I must apologize for having ignored the blog over the last two weeks. I have been intensely focused on the launch of a new project that we at Malecare have been developing. It has managed to take up every available second of my time. At this moment, I am not able to describe much about the project, but I can share with you that it involves developing an alternative platform to fund cancer research. At the current time I am working with many prostate cancer researchers to develop informational descriptions about their research. We are coming to the end of this phase and will be ready to launch the rest of the program. Needless to say, I will fill you in on the entire project as soon as possible as part of the project will involve your help.

Now, I will move on to the today’s post.

I have been having a number of conversations and emails recently about the use of estrogen for hormone therapy (ADT). I am assuming this has been prompted by my last post of

In that post I discussed estrogens as an alternative to standard hormone therapy (ADT) using luteinizing hormone-releasing hormone (LHRH) analogs. Since then I have stumbled upon an addition study examining estrogen use in ADT and its r